Theravitae, an international stem cell company says a doctor from Hawaii is believed to be one of the first patients in the world to receive not one, but two different stem cell treatments. His first treatment injected his stem cells directly into the heart muscle to treat his congestive heart failure and now he is having more stem cells injected into his coronary arteries by catheter to treat his coronary artery disease
Cary L. Hirsch, M.D., F.A.C.C., Co-director of the Cardiac Catheterization Lab at the Active International Cardiovascular Institute at Good Samaritan Hospital in Suffern, N.Y., has been appointed to the newly-created position of Medical Director for Clinical Trials, announced Michael Schnieders, Executive Vice President and Administrator for Good Samaritan Hospital.
Global Pulmonary Drug Delivery Technologies market is projected to cross US$19.1 billion by 2010, driven by rising incidence of chronic diseases. Other factors driving growth include escalating cost of therapy, expanding applications, and increasing desire for harmless and more effective therapies.
A novel gene therapy technique is safe and may be effective at staving off worsening symptoms of Parkinson's disease, according to the first scientific review of a dozen patients who have received the treatment over the last three years. The results were published in the latest issue of Lancet.
Vichai Jirathitikal has developed an oral AIDS vaccine originally named V-1. V1 is a specially formulated pill that contains HIV-1 viral antigens capable of withstanding the degradation in the stomach. As a result V1 can pass into the gastrointestinal tract and will be eventually presented by intestinal enterocytes to underlying mucosal immune cells.